OSAKA, Japan, August 6, 2021 –
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)
(“Takeda”) revised one of the KPIs for executive compensation on July 30, 2021. This revision is to update Fiscal Year 2021-2023 Performance Share Units (PSU) KPIs for Long-Term Incentive Compensation Plans from “Core Operating Profit Margin” to “Aggregated FY21-23 Underlying Core Operating Profit Margin” to reflect that it measures the aggregated margin over the FY2021-2023 performance period.
Please visit here
for the revised “Takeda’s Executive Compensation Overview”.